MLTX MoonLake Immunotherapeutics

NASDAQ
$10.80

MoonLake Immunotherapeutics (MLTX) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is a loss of $0.82 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.9% since its last earnings release on November 4, 2026.

MoonLake Immunotherapeutics Missed Consensus Estimates
Wednesday, November 4, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · After Close
Earnings Whisper
-
vs ($0.82)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $11.16

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.